Member Info for yeboha

Touk, the science is crystal clear !

That's an excellent point! Perhaps, when they feel fully prepared, they will decide to pursue that option. The more data one has at their disposal, the better informed their decisions will be. It really does come down to that fundamental truth: having access to comprehensive and relevant data can significantly enhance outcomes and strategies.

Wyn: it's hard to believe that all the world-leading scientists in their respective fields who are associated with Avacta would be deceiving us. Think about it—they have dedicated their lives to research and innovation. They wouldn't risk their hard-earned reputations for anything less than the truth. It's important to take a step back and consider the integrity and credibility of these professionals!

Obe-cel, could help up to 150 patients in the next three years, thats what it said on the page !

Or maybe i havent woken up properly yet lol

Has it, why is that ? this is a board for avacta isnt it ?

Why are we discussing the new leukemia drug that has no connection to Avacta on this board? Let me guess why: certain individuals are spreading FUD. They aren’t rivals, and there is plenty of room for both new treatments!

Aldebaran, you're spot on. Even if it just stops all the horrible side effects of the chemo, that's a win in my book. But as we all know, it does a lot more than just that!

I dont think they are

Touk : So what is this special cleaved dox that has a 40% extended half life over intravenously dosed dox?

Great question — and the answer is simpler than it sounds.

There is no “new” or “special” version of doxorubicin being created.

👉 The “special cleaved dox” is simply normal doxorubicin

BUT released inside the tumour microenvironment, not in the bloodstream — and that changes its behaviour dramatically.

Let’s break it down clearly.

🔬 1. What AVA6000 actually does

AVA6000 is:

Doxorubicin

Attached to a peptide “mask”

That can only be cut by FAP (fibroblast activation protein)

And FAP is high in many tumours but very low in normal tissue

So AVA6000 itself has a longer half-life, because it’s a stable prodrug circulating safely.

When it reaches a tumour, FAP enzymes cleave off the peptide, releasing plain doxorubicin right there in the tumour.

This is what Avacta calls “cleaved dox” or “released dox”.

🔍 2. Why does the cleaved doxorubicin appear to have a 40% longer half-life?

Not because the doxorubicin molecule is different.

But because:

✔ It is being released slowly and continuously inside tumour tissue

✔ It then “leaks back” into the blood over many hours

✔ This produces a slow-release profile

✔ This means lower peaks (Cmax) and longer persistence (t½)

So the appearance of a longer half-life is due to:

⚡ A steady trickle of dox from tumour → bloodstream over time

instead of a single sharp peak from an IV bolus.

📌 3. So what is this “special” dox?

It is:

Normal doxorubicin molecule

+

A very different release mechanism (enzyme-triggered release in tumours)

=

A radically different PK profile

This is why Avacta sees:

~40–50% lower Cmax

~40% longer plasma half-life

Much higher tumour concentrations

Much lower heart exposure

Even though the molecule is identical to standard dox.

🎯 4. Why is the half-life extension GOOD here?

For standard doxorubicin → a longer half-life is harmful (more cardiac toxicity).

For AVA6000 → a longer half-life indicates:

🟢 The prodrug is stable

🟢 Little doxorubicin is being released in the bloodstream

🟢 Tumour-specific release is occurring as designed

🟢 Slow, controlled release leads to safer exposure

So the “longer half-life” in AVA6000 is a positive biomarker for successful targeting

Thorn, LOL, I asked the exact question you wanted. Just give it a rest; you're wrong. But like I said, you keep thinking you're in the right, and we can have this exchange later on!

Cj , i have faith in him, i think he will admit he's wrong and move on

Now i await your response Thorn to see if you are actually are a man and can admit when your wrong ?

I added this to my question , this is what you wanted : What's is the half life of AVA6000 and would you say that was short or long !

Great follow‑up question. The situation with AVA6000 (Avacta’s FAP‑activated doxorubicin) is a bit nuanced. Here’s what the public data say — and whether its half-life is “short” or “long” in context.

🔍 What is the half-life of AVA6000 (released doxorubicin)

Avacta reports that the plasma half-life of doxorubicin released from AVA6000 is extended by ~40% compared to conventional doxorubicin.

GlobeNewswire

+2

Avacta Therapeutics

+2

Conventional (standard) doxorubicin has a reported terminal / effective half-life of ~35 hours in Avacta’s materials.

MarketScreener

Therefore, the half-life of the released doxorubicin from AVA6000 is roughly:

35

hours

×

1.40

≈

49

hours

35 hours×1.40≈49 hours

(This is a rough calculation based on the “~40% longer” claim.)

✅ Is that “short” or “long”?

Compared to standard doxorubicin:

It’s longer — by a significant margin (roughly 1.4×), which is meaningful for PK.

In an absolute / drug‑delivery context:

~49 hours (or thereabouts) is moderately long but not extreme. Many drugs have half-lives of hours to days. It’s not ultra‑long (e.g., weeks), but for a chemotherapy agent, it's quite useful: long enough to allow sustained exposure, but not so long that it’s permanently lingering.

In terms of benefit for AVA6000:

This longer half-life is good, for the reasons we discussed: sustained release, more time in circulation for tumour targeting, and lower peaks in plasma to reduce toxicity.

I've shown you that you're wrong, but you're too thick to see it! I can't help that, can I?

Thorn: You keep thinking you're correct, and we will have this discussion down the line, but no doubt you would have disappeared by then! Like I said, you are 100% the type of person who won’t admit when they are wrong. Quite sad, really!

OMG Thorn , the people are right on here, you are either a bit dim or just that far gone you cant see the trees through the woods

Thron : That AI has sifted through all the data and has come to an unbiased view ! just admit your wrong ? but im guessing your the sort of person who cant do that !

Thorn are you not going to reply to my comment that totally debunks your utter tripe you have been spouting about the half life ??

Thorn this is for you : I asked AI , so is it good news that Avacta has a longer half life

Yes — for AVA6000 specifically, the longer half-life is good news.

Here’s the key point:

👉 A longer half-life is bad for standard doxorubicin, but good for Avacta’s targeted version

Why? Because in AVA6000, the doxorubicin is kept “locked” and inactive in the bloodstream until it reaches tumour tissue where FAP enzymes cut it free.

That means:

✅ Why a longer half-life is GOOD for AVA6000

1. More time for the drug to reach tumours

A longer half-life means the conjugate stays in the blood longer, giving it more time to circulate, seep into tumour tissue, and get cleaved where FAP is high.

2. Less toxicity to healthy tissues

Because the doxorubicin is inactive while circulating:

A longer half-life does NOT increase toxicity

Much less free doxorubicin is in the bloodstream compared to standard doxo

Low Cmax (peak concentration) helps protect the heart

This is the opposite of standard doxorubicin, where a longer half-life would be dangerous.

3. More sustained delivery of doxorubicin INTO the tumour

The data show:

Free doxorubicin builds up in tumour tissue over time

Tumour concentrations at 24 hours are higher than plasma

This only works because the prodrug stays around long enough to be cleaved

So a longer half-life = more tumour exposure, which is exactly what you want.

4. It suggests the pre|CISION system is working

If half-life is longer and toxicity is low, it means:

The drug is circulating safely

FAP is selectively releasing active drug in the tumour

Very little active doxo is leaking into healthy tissue

This is Avacta’s entire value proposition.

⚠️ The only time a longer half-life would be bad

If AVA6000 were releasing too much doxorubicin into the bloodstream, a longer half-life would be dangerous.

But the clinical data so far show:

Very low free doxorubicin in plasma

Minimal cardiac toxicity

Good tolerability at doses where normal doxo would be harmful

So at the moment, everything points in the right direction.